PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study detects multidrug-resistant KPC-producing bacteria in Chilean wastewater for the first time

2025-09-01
(Press-News.org)

A team of Chilean researchers has identified, for the first time in the country, the presence of KPC-type carbapenemase-producing bacteria in wastewater samples from the Greater Concepción Metropolitan Area. The finding, published in the journal Biological Research, raises concerns about the environmental circulation of microorganisms with high levels of resistance to critical clinically used antibiotics and reinforces the need for surveillance within the framework of "One Health."

The research, which was part of Franco Ilabaca's Master's thesis in Microbiology, was led by Dr. Gerardo González-Rocha, director of the Antibacterial Agents Research Laboratory at the University of Concepción and thesis advisor, Dr. Andrés Opazo-Capurro, director of the FONDEF IDeA project, and Dr. Helia Bello-Toledo, thesis co-advisor, in collaboration with the MELISA Institute and other institutions. The research consisted of the collection and microbiological and genomic analysis of wastewater samples taken during 2022 at a treatment plant that serves more than 950,000 people in the Biobío Region. “The idea is to see how antibiotic resistance is not only present in bacteria found in hospitals, but can also be present in wastewater or the environment, and to emphasize that the research approach to antibiotic resistance cannot be limited to human health alone, but can also include environmental and animal health, which is known today as a One Health approach. So, the main objective was to see if we can find these resistance mechanisms that are so common in hospitals in wastewater,” explained Dr. González-Rocha.

Of a total of 205 bacterial isolates, three strains were identified as producers of the KPC enzyme, a type of carbapenemase that confers resistance to last-line antibiotics. These strains corresponded to the species Klebsiella pasteurii, Klebsiella pneumoniae subsp. pneumoniae, and Citrobacter freundii sensu stricto, all with multiple antibiotic resistance profiles and carrying the blaKPC-2 gene.

Genomic analysis also revealed that these strains contained plasmids associated with the dissemination of resistance genes and, in some cases, class 1 integrons, which increase the bacteria's ability to acquire new resistance determinants. In evolutionary terms, two of the strains analyzed showed genetic similarities with others previously identified in Asia and Europe, suggesting their possible introduction from abroad and adaptation to local contexts.

Regarding these analyses, performed using the Illumina NextSeq 500 platform, complemented by bioinformatics tools such as FastQC, Unicycler, and Bakta for genome evaluation, assembly, and annotation, along with specialized software to identify resistance genes and plasmids involved in their dissemination, Mauricio Hernández, Laboratory Head at the MELISA Institute, explained, "It was a pleasant experience for us to collaborate with Dr. González's group and support genome sequencing. This also contributes to research into multidrug resistance to antibiotics, which has become a global health problem and requires a significant increase in research."

The researchers warn that, although the detected prevalence is low (1.5%), the presence of carbapenem-resistant bacteria in urban environments represents a warning sign. Early identification allows for anticipating public health risks and implementing timely preventive measures. Therefore, it is essential to analyze wastewater and study whether treatment plants are capable of eliminating both bacteria and resistance genes.

For his part, Dr. Elard Koch, Chairman of the MELISA Institute, emphasized the importance of collaboration and knowledge dissemination: "Studies like this reinforce the vital need for strong scientific collaborations. They allow us to generate and share knowledge on topics of high relevance to society. Collaborative research is undoubtedly essential not only for scientific dissemination, but also for fostering a deeper public understanding of complex phenomena such as antimicrobial resistance."

The study was funded by the National Research and Development Agency (ANID) through the FONDEF IDeA fund and represents a concrete advance in genomic surveillance applied to the control of antimicrobial resistance in Chile.

###

This work was funded by the FONDEF IDeA Grant No. ID23I10264 awarded to A. O.-C.

Participating Researchers:

Franco Ilabaca‑Carrasco (1, 2, 3), Carlos Peña‑Raddatz (1), Claudia Torres‑Bustos (1), Mauricio Hernández‑Cea (4), Guillermo Nourdin‑Galindo (4), Pablo Saldivia‑Flandez (4), Cristian Vargas (4), Elard Koch (4), Helia Bello‑Toledo (1, 2), Gerardo González‑Rocha (1,2) and Andrés Opazo‑Capurro (1, 2).

(1) Laboratorio de Investigación en Agentes Antibacterianos (LIAA), Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile; (2) Grupo de Estudio en Resistencia Antimicrobiana (GRAM), Universidad de Concepción, Concepción, Chile; (3) Laboratorio de Biología, Departamento de Ciencias Biológicas, Facultad de Ciencias de La Vida, Universidad Andrés Bello Sede Concepción, Talcahuano, Chile; (4) Division of Biotechnology, MELISA Institute, Concepción, Chile.

END



ELSE PRESS RELEASES FROM THIS DATE:

New artificial intelligence model accurately identifies which atrial fibrillation patients need blood thinners to prevent stroke

2025-09-01
Conference: “Late Breaking Science” presentation at the European Society of Cardiology - AI driven cardiovascular biomarkers and clinical decisions Title: Graph Neural Network Automation of Anticoagulation Decision-Making Date: Embargo lifts Monday, September 1, 4:00 pm EDT Bottom Line: Mount Sinai researchers developed an AI model to make individualized treatment recommendations for atrial fibrillation (AF) patients—helping clinicians accurately decide whether or not to treat them with anticoagulants (blood thinner medications) to prevent stroke, which is currently the standard treatment course in this patient population. This model presents a completely ...

Safety of factor XI inhibition with abelacimab in atrial fibrillation by kidney function

2025-09-01
About The Study: In this secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function. These findings suggest that abelacimab may offer a particularly favorable safety profile among those with chronic kidney disease; however, larger studies are necessary to characterize the efficacy of abelacimab for stroke prevention in atrial fibrillation. Corresponding Author: To contact the corresponding author, Siddharth M. Patel, MD, MPH, email spatel@bwh.harvard.edu.  To access the embargoed study: Visit our For ...

Combination of mini-camera and AI predicts recurrent heart attack

2025-09-01
Measurements with a miniature camera inside the coronary arteries can accurately predict whether someone will suffer a recurrent heart attack. Until now, interpreting these images was so complex that only specialized laboratories could perform it. A new study from Radboud university medical center shows that AI can reliably take over this analysis and rapidly assess arteries for weak spots. A heart attack occurs when a coronary artery, which supplies the heart with blood, is blocked by a blood clot. This can occur when atherosclerosis causes artery narrowing, resulting in the heart receiving too little oxygen. Treatment typically ...

Study Reveals Details of Overactive Immune System in Patients with Chronic Fatigue Syndrome (ME/CFS)

2025-09-01
Patients with chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) have heightened innate immune responses to bacteria, viruses and fungi. While these responses are essential to fight infection, they can cause damage when unchecked. Led by researchers at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health with a multicenter team of leading ME/CFS researchers, the new study reveals molecular-level details into the syndrome’s lasting effects on inflammation and immune response that could inform the development of targeted therapeutic interventions to ...

UTSA and UT Health San Antonio complete merger to become The University of Texas at San Antonio

2025-09-01
SAN ANTONIO, Sept. 1, 2025 – UTSA and The University of Texas Health Science Center at San Antonio (UT Health San Antonio) today merged to form The University of Texas at San Antonio (UT San Antonio), a premier global university that is deeply committed to making lives better for the communities it serves. As a merged institution, UT San Antonio now ranks as the third-largest public research university in Texas according to annual research expenditures, behind only Texas A&M University and the University of Texas at Austin. UT San Antonio’s comprehensive enterprise now includes approximately 40,000 students, 17,000 employees and more than $486 million in annual ...

Helicobacter pylori screening after acute myocardial infarction

2025-09-01
About The Study: Among unselected patients with acute myocardial infarction, routine H pylori screening did not significantly reduce the risk of upper gastrointestinal bleeding. Corresponding Author: To contact the corresponding author, Robin Hofmann, MD, PhD, email robin.hofmann@ki.se. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support. Embed this link to provide your readers ...

Solar Orbiter traces superfast electrons back to Sun

2025-09-01
The European Space Agency-led Solar Orbiter mission has split the flood of energetic particles flung out into space from the Sun into two groups, tracing each back to a different kind of outburst from our star. The Sun is the most energetic particle accelerator in the Solar System. It whips up electrons to nearly the speed of light and flings them out into space, flooding the Solar System with so-called ‘Solar Energetic Electrons’ (SEEs). Researchers have now used Solar Orbiter to pinpoint the source of these energetic electrons and trace what we see out in space back to what’s actually ...

GaN-based electron beam technology from Nagoya University startup poised to overcome critical semiconductor manufacturing challenges at KIOXIA

2025-09-01
NAGOYA, Japan — In late September 2025, KIOXIA Iwate Corporation (Koichiro Shibayama CEO) will begin evaluating a GaN-based e-beam technology developed through joint research between Photo electron Soul Inc. (PeS; Takayuki Suzuki CEO), a Nagoya University startup, and the Amano–Honda Laboratory at Nagoya University. PeS has developed a next-generation electron gun specialized for GaN (gallium nitride) photocathodes and has demonstrated its effectiveness for semiconductor inspection and metrology (I&M), enabling electron microscopy of nanoscale transistors and high-aspect-ratio structures. These ...

Circle versus rectangle: Finding ‘Earth 2.0’ may be easier using a new telescope shape

2025-09-01
by Prof Heidi Newberg The Earth supports the only known life in the universe, all of it depending heavily on the presence of liquid water to facilitate chemical reactions. While single-celled life has existed almost as long as the Earth itself, it took roughly three billion years for multicellular life to form. Human life has existed for less than one 10 thousandth of the age of the Earth. All of this suggests that life might be common on planets that support liquid water, but it might be uncommon to find life that studies the universe and seeks to travel ...

Metformin changes blood metal levels in humans

2025-09-01
The widely used diabetes drug metformin changes blood metal levels in humans. The Kobe University study is an important step in understanding the drug’s many actions and designing better ones in the future. Metformin is the most widely prescribed diabetes drug in the world. Apart from lowering blood sugar levels, it is also known to have a broad range of beneficial side effects such as against tumors, inflammations and atherosclerosis. However, although it has been used for more than 60 years ...

LAST 30 PRESS RELEASES:

Depression may make learning to avoid unpleasant events harder

Study sheds light on how pediatric brain tumors grow

Rare seasonal brain shrinkage in shrews is driven by water loss, not cell death

AI co-pilot boosts noninvasive brain-computer interface by interpreting user intent

Black adults face heart failure nearly 14 years earlier than white patients

Study detects multidrug-resistant KPC-producing bacteria in Chilean wastewater for the first time

New artificial intelligence model accurately identifies which atrial fibrillation patients need blood thinners to prevent stroke

Safety of factor XI inhibition with abelacimab in atrial fibrillation by kidney function

Combination of mini-camera and AI predicts recurrent heart attack

Study Reveals Details of Overactive Immune System in Patients with Chronic Fatigue Syndrome (ME/CFS)

UTSA and UT Health San Antonio complete merger to become The University of Texas at San Antonio

Helicobacter pylori screening after acute myocardial infarction

Solar Orbiter traces superfast electrons back to Sun

GaN-based electron beam technology from Nagoya University startup poised to overcome critical semiconductor manufacturing challenges at KIOXIA

Circle versus rectangle: Finding ‘Earth 2.0’ may be easier using a new telescope shape

Metformin changes blood metal levels in humans

Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation

Fractional flow reserve–guided complete vs culprit-only revascularization in non–ST-elevation myocardial infarction and multivessel disease

Participation of women in cardiovascular trials from 2017 to 2023

Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction

Changes in biology of internal fat may be the leading cause of heart failure

Transcatheter or surgical treatment of patients with aortic stenosis at low to intermediate risk

Promising new drug for people with stubborn high blood pressure

One shot of RSV vaccine effective against hospitalization in older adults for two seasons

Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults

Clonal hematopoiesis and risk of new-onset myocarditis and pericarditis

Risk of myocarditis or pericarditis with high-dose vs standard-dose influenza vaccine

High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults

Prevalence, determinants, and time trends of cardiovascular health in the WHO African region

New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers

[Press-News.org] Study detects multidrug-resistant KPC-producing bacteria in Chilean wastewater for the first time